CJC-1295 vs Ipamorelin: GHRH Analog vs Ghrelin Mimetic

CJC-1295 is a modified GHRH (Growth Hormone Releasing Hormone) analog. Naturally occurring GHRH has a minutes-long half-life and pulses GH release during the night and post-exercise. CJC-1295 without DAC (Drug Affinity Complex) has a ~30-minute half-life — long enough for dosed research but requires multiple daily doses. CJC-1295 with DAC binds to albumin, extending the half-life to 6–8 days — a single injection produces elevated GH and IGF-1 for nearly a week. Both variants act on the GHRH receptor to amplify the amplitude of endogenous GH pulses.

Ipamorelin acts on a different receptor entirely: the GHS-R1a (ghrelin receptor). It is one of the most selective ghrelin mimetics in research literature — it stimulates GH release without significantly affecting cortisol, prolactin, or aldosterone, which is why researchers use it to isolate GH-mediated effects from stress-axis confounds. Ipamorelin adds pulse frequency rather than amplitude: it causes the pituitary to fire GH pulses at moments it otherwise would not.

Combining a GHRH analog with a ghrelin mimetic is synergistic because the two pathways gate GH release independently. When both signals fire together, GH release exceeds the additive sum of each alone — documented in animal and human studies since the late 1990s. The resulting GH pulse is larger and cleaner than what either peptide produces alone.

In practice, most research protocols that study GH-mediated anabolism (lean tissue accretion, IGF-1 response, recovery biology) use CJC-1295 + Ipamorelin at matched timing — subcutaneous injection 20–30 minutes pre-sleep or post-exercise to coincide with endogenous GH peaks.